drug

(ertugliflozin + sitagliptin phosphate)

Marketedupdated 2mo ago

by Merck Sharp & Dohme (IA) LLC

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 24, 2026

140 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Oct 21, 2030formulationUS 93082044.3y
Oct 21, 2030formulationUS 93082044.3y
Oct 21, 2030method-of-use (U-2214)US 94399014.3y
Oct 21, 2030method-of-use (U-2214)US 94399014.3y
Jul 13, 2030compositionUS 80805804.0y
Jul 13, 2030compositionUS 80805804.0y
May 24, 2027patentUS 7326708*PED321d
May 24, 2027patentUS 7326708*PED321d
Nov 24, 2026compositionUS 7326708140d
Nov 24, 2026compositionUS 7326708140d

Data sources

ClinicalTrials.gov

last refreshed 53m ago

Found something off?